Shared on29 Aug 25Fair value Increased 75%
The notable upward revision in P3 Health Partners’ price target is primarily supported by a significant decline in its forward P/E ratio, indicating improved earnings expectations, with the fair value estimate increased from $8.00 to $14.00. What's in the News P3 Health Partners raised earnings guidance, projecting total revenues between $1.35 billion and $1.5 billion for fiscal 2025.
Shared on24 Apr 25Fair value Decreased 48%
AnalystConsensusTarget has decreased future PE multiple from 4.4x to 2.2x.
Shared on17 Apr 25Fair value Increased 673%
AnalystConsensusTarget has decreased revenue growth from 2.5% to 1.6%, increased future PE multiple from 1.0x to 4.4x, decreased discount rate from 10.2% to 9.0% and increased shares outstanding growth rate from 0.0% to 0.1%.